Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terazosin in Parkinson's Disease
NCT03905811Phase 2Completed
- Start
- Sep 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of terazosin in Parkinson's disease (PD). Primary endpoint: Incidence of Intervention-related Adverse Events Between Treatment Arms at 12 weeks. Started Sep 2019; status: completed.
02
Drugs
terazosin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03905811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03905811.